Starting Material Stabilization
Treg therapy starts from a patient or donor leukapheresis product, and Tregs are only a small fraction of the collected cells. Between collection and processing, the cells are exposed to temperature shifts, handling, and surface contact, and viability at this stage affects the yield of Tregs recovered. A stabilizing protein supports cell health through transport and hold, before isolation begins.
Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.
- Commonly replaces
- Serum or plasma-derived albumin used to stabilize collected apheresis cells.